Jump to content
PathLabTalk

exlimey

Members
  • Posts

    315
  • Joined

  • Last visited

  • Days Won

    25
  • Country

    United States

Everything posted by exlimey

  1. That conflicts with you original post: "Set up 4 units of A Pos unit and found to be incompatible. Then we set up 3 A Rh D negative units and found to be incompatible." I'm confused.
  2. Two thoughts: 1. The other D+ cells on the panel probably have "homozygous expression", whereas the Ro donor may be a single dose. You may just be seeing a dosage effect. 2. The Ro cell may be DcatIV, which is missing a few epitopes found on normal expressions of D antigen (I don't remember the details). If the donor is heterozygous (single dose), expressing only the DcatIV gene, the anti-D in the patient may not have the ability to react with the modified expression. If Malcolm Needs reads this, I'm sure he'll correct my terminology deficits to the more modern versions.
  3. On another track......why the switch to Rh-negative units ?
  4. This doesn't fit the pattern for an antibody to a low incidence antigen - in this case, all 7 group A units are incompatible and the 4 group O units are compatible.
  5. Here's my 2-cents, 2-pennies, or 2-any other small denomination coins: First, I am NOT a regulatory expert, but I am familiar with assay development and validation. All assays should be controlled in some fashion, to give the practitioners some confidence that the results are valid AND that batch-to-batch variation is limited. In a titration, especially a serological titration, this is a little more difficult than having one or two pass/fail samples that are typically included in many laboratory tests. If a control is needed for a titration, it doesn't need to be the same specificity as the test antibody (as Malcolm highlights). Ideally, yes, but not necessarily. It does need to be reliable/robust and give the same end point each time, even with the acknowledged variations in serological tests (reagents, test cells, techs, etc.). Tube testing is notoriously variable, while gel testing is believed to reduce some of those nuances. As Malcolm suggests, it might be necessary to have a control for an IgM titration (ABO) and/or a different one for an IgG titration. At the very least, the end-points may be different. An IgM control might be as simple your routine anti-A reagent; a simple IgG control might be an IAT-reactive anti-D or other specificity. A clever option might be a control that contains both - an IgM component and an IgG component. If a test system is adequately controlled each time (and passes), in my opinion, there is no reason to routinely perform parallel testing of successive patient samples. Retention samples might be useful for investigatory reasons if/when a patient's antibody titration changes radically from one sample to the next, or if there's some other medical indication. I getting a sense of deja vu, I think I've written this before.
  6. Good thinking. Might be interesting to see if there's anything in an eluate....
  7. Might be a rare IgG anti-A1 - you may not see in in the Reverse (presumably IS or buffer-only gel card), but is detected when you do anything with an antiglogulin reagent. You could try doing the Reverse by IAT. The DAT may just be a red herring, but it might represent a weird autoantibody that favors group A cells.
  8. Please excuse my ignorance, but how can a "DAT Control" not have an antiglobulin reagent?
  9. CD = chloroquine diphosphate. A chemical treatment to remove immunoglobulins from red cells, in the hope of getting a negative DAT, thereby allowing the use of antiglobulin-reactive antisera without interference from a positive DAT.
  10. Please supply the reference for this absolute nonsense. It sounds like I would enjoy reading such fiction.
  11. I agree with Malcolm - all the best people are DCeDCe.☺ I also agree with his analysis. The differences you are seeing are probably because you are not doing as complete an adsorption as the IRL. Indeed, this partial and sequential adsorption process was the heart of the early work by Dr. Issitt (and others) when they were trying to determine the specificities of autos. Most warm autoantibodies mimic Rh specificities (there are exceptions). The older literature is full of anti-e-like autos and antibodies to compound antigens (Ce, cE, etc.). There are also a smattering of anti-D-like autos. Not uncommon, by any means. Some labs used to make an effort to ID autos, but in recent years, time and money have have almost eliminated this potentially interesting technical challenge.
  12. A very good point, Anna. The same applies to anything done "off-label", regardless of how much validation has been done.
  13. I think you're joking, but just in case...... It's a simple C1 x V1 = C2 x V2 calculation. One of the few times when algebra gets applied outside of high school. To do this accurately, you must first know the hematocrit (concentration) of your "packed cells" - this will be used as C2. For this example, let's say the hct is 75%. C1 = desired hematocrit (concentration) - 3%; V1 = desired volume - for this example, let's say we want 100 mL of 3% cells. Using the formula and information above.... 3 x 100 = 75 x V2, which resolves to 3 x 100 ÷ 75 = 4 mL. Ergo: 4 mL of "packed cells" in 100 ml pf PBS will yield ~3% suspension. This process works for low cell concentrations where the added RBC volume is only a small portion of the whole (4 mL added to 100 mL). If you try to make higher concentrations, you have to take the RBC volume into consideration as part of the whole volume.☺
  14. ANORRIS, I think you might need a few more details in your question before anyone can lend advice.
  15. Well said, John. We've all been in positions where "extra work" was logical because either the original request was wonky or we did it for our own sanity.
  16. First step: Is it reacting with autologous cells ? Fairly easy to make that call, IF the patient is untransfused. If the patient is transfused, it gets more difficult, if not impossible. Any reasonably competent IRL should be able to help. If necessary, they would be able to perform adsorptions and/or test rare cells. They may even be able to isolate autologous cells from a transfused patient.
  17. I think Scott is saying that there is still a cost associated with each test, regardless of billing. Socialized medicine bean-counters have a very real interest in making things efficient and cost effective. Redundant or unnecessary testing is the target in such situations.
  18. The key question: Is it auto or allo ? This may be difficult to prove if the patient has been transfused. If it is an autoantibody, I agree with Malcolm's position - who cares? However, if the autocontrol is nonreactive, you may have to consider other things. Beware anti-Vel and anti-PP1pk (-Tja). These can behave like cold-reactive AUTO antibodies, i.e., demonstrate panagglutination, abolished reactivity by pre-warmed tests, etc. There is at least one case (published by Jill Storry) of an anti-Vel that was "dismissed" as a cold auto (it was rendered nonreactive by pre-warming). The patient was transfused with random cells and had a fatal hemolytic reaction.
  19. I would check the regulations VERY carefully. I suspect it would be very difficult to make this kind of thing mandatory, especially if there is some arbitrary cutoff (transfusions/yr). On the other hand, if your boss would LIKE you to participate, it might take some clever moves to convince them to decline. Good luck.
  20. A serious finger wagging ????? Twelve lashes with a wet noodle ????? A stern, disapproving look ?????
  21. Perfect ! Throw in a risk of workers' comp. and the argument is won quickly. Nicely played.
  22. I agree too. I find it additionally perplexing that that information from these types of surveys usually takes a few years to be compiled and published. Not much use after the fact.
  23. Fascinating.....voluntary, but, it appears, strongly encouraged. I wonder in how many institutions this has been translated to "mandatory"? I lean toward R1R2's position - don't do it, especially if it is indeed a "doozy" or a "stinker". We're all busy enough already. Unless the survey organizers (FDA) are going to provide funding for such an exercise......
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.